drugset / Trial / NCT05455658
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
Phase 2
Active not recruiting
33 enrolled
University of Washington
National Cancer Institute (NCI) · collabUniversity of Wisconsin, Madison · collab
NaSingle-groupOpen-labelPrevention
Summary
This phase II trial studies the effect of DNA plasmid based vaccine (STEMVAC) in treating patients with patients with stage IB-III triple negative breast cancer. STEMVAC may wake up the immune system in patients who have had a diagnosis of triple negative breast cancer and have been treated. STEMVAC targets proteins that are expressed on breast cancer cells and works by boosting the immune system to recognize and destroy the invader cancer cell proteins that are causing the disease. The purpose of this trial is to test the immune system's response to STEMVAC.
Timeline
- Start
- 2022-11-17
- Primary completion
- 2026-07-16
- Completion
- 2028-07-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STEMVAC | Vaccine | — | Intravenous |
| Background | sargramostim | Protein / enzyme biologic | — | Other |